Table 1.

Summary of the study population.

Total number	n = 247
(Diagnosed with CML, attended KEH hematology between 01/01/2011 and 31/12/2021)
Patients excluded	n = 41
(Attendance at the clinic which did not fall within the study period, detection of mutations which predated the study period, and/or an insufficiency of data)
Patients included	n = 206
(≥12 years of age, BCR‐ABL1 positive, commenced on Imatinib)
Patients with mutations	n = 60 (29.1%)
HIV status	Positive	Negative	Unknown
	n = 11 (18.3%)	n = 40 (66.7%)	n = 9 (15.0%)
Age	≥50 years	<50 years
	n = 20 (33.3%)	n = 40 (66.7%)

Abbreviations: CML, chronic myeloid leukemia; KEH, King Edward VIII Hospital.